Sheets Smith Wealth Management Decreases Position in IQVIA Holdings Inc. $IQV

Sheets Smith Wealth Management reduced its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 16.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,194 shares of the medical research company’s stock after selling 7,367 shares during the period. Sheets Smith Wealth Management’s holdings in IQVIA were worth $6,514,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Ameliora Wealth Management Ltd. acquired a new stake in shares of IQVIA in the fourth quarter worth approximately $25,000. International Assets Investment Management LLC acquired a new position in IQVIA in the 4th quarter valued at $27,000. Gilpin Wealth Management LLC acquired a new stake in IQVIA during the 4th quarter worth $27,000. CrossGen Wealth LLC acquired a new stake in IQVIA during the 4th quarter worth $28,000. Finally, Measured Wealth Private Client Group LLC purchased a new stake in shares of IQVIA during the third quarter worth $30,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Royal Bank Of Canada started coverage on shares of IQVIA in a research note on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 price target on the stock. Morgan Stanley reiterated an “equal weight” rating and issued a $200.00 price objective (down from $225.00) on shares of IQVIA in a report on Wednesday. Weiss Ratings lowered shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a report on Sunday, June 14th. Finally, Evercore reaffirmed an “outperform” rating and issued a $185.00 price target on shares of IQVIA in a report on Wednesday, April 8th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $222.56.

IQVIA Stock Up 0.2%

Shares of NYSE IQV opened at $168.14 on Friday. The company has a market capitalization of $28.06 billion, a P/E ratio of 20.84, a P/E/G ratio of 1.44 and a beta of 1.21. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. The company has a 50 day simple moving average of $173.63 and a 200-day simple moving average of $191.68. IQVIA Holdings Inc. has a 1 year low of $153.01 and a 1 year high of $247.04.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. The firm had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm’s quarterly revenue was up 8.4% on a year-over-year basis. During the same period in the prior year, the firm posted $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, equities research analysts predict that IQVIA Holdings Inc. will post 11.6 earnings per share for the current year.

IQVIA announced that its Board of Directors has initiated a share repurchase program on Thursday, May 7th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s management believes its shares are undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.